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Abstract
Introduction: Multicentric Castleman’s Disease (MCD), a lymphoproliferative disorder associated with Human
Herpes Virus-8 (HHV-8) infection, is increasing in incidence amongst HIV patients. This condition is associated with
lymphadenopathy, polyclonal gammopathy, hepato-splenomegaly and systemic symptoms. A number of small
studies have demonstrated the efficacy of the anti-CD20 monoclonal antibody, rituximab, in treating this condition.
Case presentation: We report the case of a 46 year old Zambian woman who presented with pyrexia, diarrhoea
and vomiting, confusion, lymphadenopathy, and renal failure. She rapidly developed multiple organ failure
following the initiation of treatment of MCD with rituximab. Following admission to intensive care (ICU), she
received prompt multi-organ support. After 21 days on the ICU she returned to the haematology medical ward,
and was discharged in remission from her disease after 149 days in hospital.
Conclusion: Rituximab, the efficacy of which has thus far been examined predominantly in patients outside the
ICU, in conjunction with extensive organ support was effective treatment for MCD with associated multiple organ
failure. There is, to our knowledge, only one other published report of its successful use in an ICU setting, where it
was combined with cyclophosphamide, adriamycin and prednisolone. Reports such as ours support the notion that
critically unwell patients with HIV and haematological disease can benefit from intensive care.
Introduction
The spectrum of HIV-associated disease on the ICU has
changed markedly since the widespread adoption of
combination antiretroviral therapy (Highly Active Anti-
retroviral Therapy, HAART) in the late 1990s. Whilst
the incidence of opportunistic infections has decreased,
that of several neoplasms, including Multi-centric Cas-
tleman’s Disease (MCD) and Hodgkin’sl y m p h o m ai s
increasing. MCD is a lympho-proliferative disorder asso-
ciated with Human Herpes Virus-8 (HHV-8) infection,
characterised by fever, lethargy, anaemia and lymphade-
nopathy. Lymph node histology typically reveals angio-
follicular hyperplasia and plasma cell infiltration. There
is as yet no accepted therapeutic gold standard for
MCD. Initial treatment approaches involved chemother-
apy with agents such as vinblastine, etoposide and dox-
orubicin plus corticosteroids. More recently the anti-
CD20 monoclonal antibody, rituximab, has been used.
This targets HHV-8-infected plasmablasts, which co-
express the B cell antigen CD20. Small case series of
patients with MCD have shown rituximab to be an
effective therapy in patients that do not require organ
support on the intensive care unit [1-3].
Case Presentation
A 46 year old Zambian woman was referred from
another hospital with a 4 week history of fevers, night
sweats, vomiting, diarrhoea, and renal impairment. She
had been diagnosed HIV positive in 2005, and started
on HAART one year later. She had previously been trea-
ted for Herpes simplex virus infection, Cytomegalovirus
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(PCP). At referral her blood CD4 count was 480 × 10
6/
L (range in HIV negative populations, 400-1500 × 10
6/
L); and she had an undetectable plasma HIV load. On
arrival at our centre, she was confused, and had obvious
pitting oedema of both lower limbs, widespread lympha-
denopathy, and hepato-splenomegaly. Investigations
(Table 1) revealed anaemia, leucocytosis, thrombocyto-
paenia, and acute renal and liver dysfunction.
A CT scan showed hepato-splenomegaly and gross
lymphadenopathy involving the thorax, abdomen and
pelvis (Figure 1). Inguinal lymph node excision biopsy
confirmed the clinical suspicion of Multi-centric Castle-
man’s disease (MCD) (Figure 2). Rituximab (375 mg/m
2)
together with hydrocortisone and rasburicase, was admi-
nistered as specific treatment. She developed rapidly
progressive metabolic acidosis, oliguria, and rising
serum creatinine and was admitted to the ICU for hae-
mofiltration. Antiretroviral therapy was continued on
the ICU with ritonavir-boosted lopinavir and saquinavir.
Abacavir and lamivudine, which the patient was already
taking, were stopped because of their association with
lactic acidosis and hepatic steatosis.
Following admission to ICU she rapidly became hypo-
tensive, hypoglycaemic, coagulopathic and more anae-
mic. A possible basis for this could have been the
systemic manifestations of a “cytokine storm” associated
with MCD; increased expression of IL-6 is typical of
MCD. Vasopressor and inotropic support with noradre-
naline and dobutamine was required to maintain an
adequate mean arterial pressure (MAP). Because of
rapidly escalating requirements for noradrenaline she
received a continuous infusion of hydrocortisone (10
mg/h) as per local departmental protocol, to treat prob-
able relative adrenal insufficiency. Empirical antibiotics
and antifungal agents were given to treat sepsis as a
potential cause for ensuing multi-organ dysfunction, and
she required a continuous infusion of 20% dextrose for
refractory hypoglycaemia. To treat her acute renal fail-
ure and profound metabolic acidosis (serum lactate of
18.5 mmol/L), haemofiltration was undertaken with
large volume 5 litre cycles (~90 ml/kg/hour) of lactate-
free replacement fluid. This strategy was adopted to
target early shock reversal and removal of IL-6,
increased expression of which is a hallmark feature of
MCD.
The chest radiograph progressed over four days to
bilateral diffuse patchy consolidation (Figure 3), asso-
ciated with greatly increased oxygen requirements (FiO2
0.8), and consistent with a diagnosis of acute respiratory
distress syndrome (ARDS). The patient became drowsy
and hypercapnic. Her trachea was therefore intubated,
and mechanical ventilation was commenced.
She developed epistaxis and bleeding from insertion
sites of arterial, central venous, and haemofiltration
catheters. She had a positive direct Coombs’ test consis-
tent with autoimmune haemolytic anaemia (AIHA), a
recognised association of MCD. In addition she had ele-
vated prothrombin (PT) and activated partial thrombo-
plastin times (APTT), reduced platelets and reduced
serum fibrinogen consistent with disseminated intravas-
cular coagulation (DIC). She received methylpredniso-
lone, folinic acid, and red cell concentrate to treat
anaemia; plus cryoprecipitate, fresh frozen plasma, vita-
min K, and platelets for DIC. In addition to this exten-
sive physiological support, her Castleman’s disease was
treated with weekly infusions of the anti-CD20 mono-
clonal antibody, rituximab, for four weeks.
From day 10 there was evidence of clinical improve-
ment. She had a tracheostomy in the second week of
her ICU stay, and she was slowly weaned from inotro-
pic/vasopressor, ventilatory, and finally renal support. At
day 21 of her ICU admission, she was discharged to the
ward to complete her treatment with rituximab, and to
continue rehabilitation from global muscle weakness,
and reduce dependence on her tracheostomy. The
patient was discharged home, in remission from her dis-
ease, after 149 days in hospital. When last seen in clinic
she remained in remission and living independently 14
months from her treatment.
Discussion
Survival of patients with HIV admitted to the ICU has
improved substantially in the last 10 years, with HIV
patients now being able to expect a similar chance of
survival through to hospital discharge as general medical
patients admitted to the ICU. The basis for this
improvement is likely to be multifactorial, reflecting bet-
ter understanding of HIV-associated disease, the avail-
ability of new combination antiretroviral therapy, the
improved care of HIV patients both outside and within
the ICU, and protective ventilation strategies for HIV
patients with respiratory failure and acute lung injury.
Prognostic factors previously shown to be associated
with a poor outcome in HIV patients admitted to ICU
are low CD4 count and advanced HIV disease stage,
acute illness severity (SAPS I: simplified acute
Table 1 Laboratory investigations on admission to Royal
Free Hospital Haematology unit
Haemoglobin 8.4 g/dl Urea 56 mmol/l
White Cell Count 17 × 10
9/l Creatinine 367 μmol/l
Neutrophils 13 × 10
9/l Bilirubin 101 μmol/l
Platelets 43 × 10
9/l Aspartate transaminase 185 IU/l
Prothrombin time 20.5 seconds Albumin 18 g/l
Fibrinogen 5.4 g/l Lactate 8.6 mmol/l
C-reactive protein 140 mg/l
Johns et al. Journal of Medical Case Reports 2010, 4:32
http://www.jmedicalcasereports.com/content/4/1/32
Page 2 of 6physiology score I; or APACHE II: acute physiology &
chronic health evaluation II), and the need for, and
duration of, mechanical ventilation whilst on the ICU
[4]. In addition, a haematological malignancy also inde-
pendently further confers a poor prognosis. Such
patients typically have severely impaired host defences
and the undertaking of invasive procedures, such as
endotracheal intubation and central venous cannulation,
carries a major risk of infection.
Cornet et al [5] reported an ICU mortality rate of 60%
for haemato-oncological patients compared with a rate
of 27% for general critically ill patients. They also high-
lighted the poor long-term prognosis, with a 1 year
mortality of 88% for haemato-oncological patients. How-
ever, such patients may not fare so badly on ICU if
organ support facilitates administration of a specific
therapy for a treatable condition. Benoit et al [6] have
recently described successful outcomes in severely ill
patients with haematological malignancies who receive
intravenous chemotherapy in intensive care. Hence
admission to ICU for specific therapy can be lifesaving.
The gold standard therapy for HIV-associated MCD is
yet to be established. Vinblastine, etoposide and doxoru-
bicin plus corticosteroids have all been used previously.
Etoposide has been shown to be effective with resolution
of systemic symptoms during its administration. How-
ever it has not been associated with prolonged remis-
sion. Interruption of chemotherapy usually results in
clinical recurrence and most patients remain che-
motherapy-dependent for life. In addition its use can be
associated with cytopaenias. The use of etoposide would
have been considered as adjuvant therapy in our case
had the MCD not responded to rituximab monotherapy.
In contrast rituximab is well tolerated and has been
shown to be effective in case reports and series [1-3].
The role of rituximab in therapy for critically ill patients
is less well established. In previously published reports,
those admitted to ICU did not survive. Recently,
Figure 1 Multi-detector computed tomography (CT) thorax and abdomen with intravenous contrast enhancement showing
hepatosplenomegaly, axillary and abdominal lymphadenopathy.
Figure 2 Inguinal lymph node biopsy: histology characteristic of MCD: (A) Haematoxylin & Eosin stained section of lymph node (original
magnification × 2.5) showing effaced architecture with few residual follicles. (B) infiltration with large blastic cells (PB, original magnification ×
60). (C) Immunostaining reveals blastic cells express HHV-8 (positive cells are brown, original magnification × 60).
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tion with cyclophosphamide, adriamycin and predniso-
lone, in the ICU setting, has been described [7].
In our patient, the clinical presentation was consistent
with a systemic illness with a large inflammatory/infec-
tive component. The patient was originally from a coun-
try with endemic mycobacterial and fungal infection.
Investigations therefore were undertaken to exclude a
variety of possible causes - including disseminated
mycobacterial and fungal disease, as well as lymphoma-
like conditions, such as MCD. Prompt diagnosis was
made following lymph node biopsy. The decision to
biopsy an inguinal lymph mode, rather than a cervical
node was based on the clinical findings of a large and
easily palpable inguinal lymph node mass. Although
small volume bilateral cervical lymphadenopathy was
present, this was far less clearly abnormal than the groin
lymph nodes. A particular issue in HIV patients is the
presence of persistent generalised lymphadenopathy,
which represents an immune response directed against
HIV. This typically results in findings similar to the cer-
vical adenopathy present in this patient; and therefore
neck biopsy may have in fact slowed the diagnostic
process.
Antiretroviral therapy was continued, but modified on
the ICU. Notably the patient had been using antiretro-
viral therapy (HAART) for two years prior to her pre-
sentation to our service. She had had a persistently
undetectable plasma HIV load (<50 copies/mL). Her
nucleoside reverse transcriptase inhibitors (abacavir and
lamivudine) were stopped because of their association
with lactic acidosis and hepatic steatosis. Although it
would be surprising for this to occur after such a pro-
longed time on these drugs, it was important to
Figure 3 Chest X-ray showing bilateral diffuse infiltrates.
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have resulted from these agents; and which in turn
could have contributed to acidosis. Monotherapy with
ritonavir-boosted protease inhibitors is a useful treat-
ment option in patients who are intolerant or resistant
to other agents [8]. The approach is particularly success-
ful in patients who have already suppressed their plasma
HIV load, such as in this case.
Her condition progressed rapidly to one of multi-
organ failure requiring a high level of support on the
ICU. Supportive strategies included mechanical ventila-
tion for acute respiratory distress syndrome; circulatory
support with inotropes/vasopressors and corticosteroids;
and high volume haemofiltration for renal failure and
severe metabolic acidosis. Corticosteroids were used
empirically to treat probable underlying relative adrenal
insufficiency. This occurs in up to 25% of critically ill
patients with sepsis. Surviving Sepsis guidelines [9] pub-
lished in 2004 do not suggest mandatory testing (by
adrenocorticotrophic hormone: ACTH stimulation test)
unless there is strong suspicion of undiagnosed primary
adrenal insufficiency. The 10 mg/h infusion used in our
patient was in line with the recommended 24 hour total
dose of 200-300 mg. High volume haemofiltration was
undertaken to target early shock reversal and removal of
IL-6, increased expression of which is a hallmark feature
of MCD. In animal studies, such a strategy is associated
with improved haemodynamics and gas exchange,
reduced immuno-paresis and increased survival [10].
The length of hospital stay post ICU discharge for our
patient largely reflects the need for weaning from
respiratory support and rehabilitation. Patients such as
ours often experience profound muscle weakness (ICU-
acquired weakness) after mechanical ventilation on
intensive care, and require intensive physiotherapy, as
well as nutritional, psychological and social support.
Conclusion
Our patient’s successful outcome can be attributed to
relatively simple treatment for MCD: that is rituximab;
and extensive multi-organ care support on the ICU.
Rituximab is a newly-established therapy for MCD [1].
Its efficacy has thus far been chiefly demonstrated in
limited studies of patients outside of the intensive care
setting. Recent literature suggests ICU admission and
support can be beneficial for haemato-oncological
patients to facilitate specific chemotherapy [6]. Consis-
tent with this notion, our report illustrates the benefit of
ICU support during rituximab treatment for HIV asso-
ciated MCD.
Consent
Written informed consent was obtained from our
patient for publication of this case report. A copy of the
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